Company Filing History:
Years Active: 2017
Title: The Innovations of Kristian Sass Bak-Jensen
Introduction
Kristian Sass Bak-Jensen is a notable inventor based in Copenhagen V, Denmark. He has made significant contributions to the field of medical science, particularly in the development of compounds that can aid in the treatment of various metabolic disorders. His work is particularly relevant in today's health landscape, where conditions such as diabetes and obesity are increasingly prevalent.
Latest Patents
Kristian holds one patent for N-terminal modified FGF21 compounds. This patent describes analogs of FGF21 that carry a modifying, substituted ethylene or benzyl group. These compounds have potential applications in the treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and Non-Alcoholic Fatty Liver Disease (NAFLD).
Career Highlights
Kristian is currently employed at Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care and other chronic conditions. His role at Novo Nordisk allows him to work at the forefront of medical innovation, contributing to the development of therapies that can improve patient outcomes.
Collaborations
He collaborates with talented colleagues, including Tina Moeller Tagmose and Patrick William Garibay. These partnerships enhance the research and development efforts at Novo Nordisk, fostering an environment of innovation and creativity.
Conclusion
Kristian Sass Bak-Jensen's work exemplifies the impact of innovative thinking in the medical field. His contributions to the development of FGF21 compounds highlight the importance of research in addressing critical health issues. Through his efforts, he continues to pave the way for advancements in treatment options for metabolic diseases.